CRISPR Therapeutics Inkomsten in het verleden
Verleden criteriumcontroles 0/6
De winst van CRISPR Therapeutics is gedaald met een gemiddeld jaarlijks percentage van -27%, terwijl de winst van de Biotechs -industrie jaarlijks groeide met 19.1%. De inkomsten zijn daalde met een gemiddeld percentage van 7% per jaar.
Belangrijke informatie
-27.0%
Groei van de winst
-25.1%
Groei van de winst per aandeel
Biotechs Groei van de industrie | 17.0% |
Inkomstengroei | -7.0% |
Rendement op eigen vermogen | -12.4% |
Nettomarge | -118.1% |
Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Crispr Therapeutics Q3 Earnings: No Casgevy Revenue, But Plenty Of Optimism
Nov 11Here's What Analysts Are Forecasting For CRISPR Therapeutics AG (NASDAQ:CRSP) After Its Third-Quarter Results
Nov 07Crispr Therapeutics: Poised For A Major Turnaround
Oct 28CRISPR Therapeutics AG (NASDAQ:CRSP) Investors Are Less Pessimistic Than Expected
Oct 02Crispr Therapeutics: Casgevy Now Active Across 35 Treatment Centres
Sep 13Here's Why We're Not At All Concerned With CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Situation
Sep 04Crispr's Casgevy Launch: Promising Start, Uncertain Future
Aug 14A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Aug 09Crispr Therapeutics Q2 Earnings: Casgevy Updates Underline 'Blockbuster' Potential
Aug 07Crispr Therapeutics Remains Expensive, With Slower Casgevy Monetization And Patent Battle
Jul 13Crispr Therapeutics: Beaten Down But Not Broken
Jul 07CRISPR Therapeutics AG's (NASDAQ:CRSP) Share Price Could Signal Some Risk
Jun 18Crispr Therapeutics, Futurism-Turning-Commercial, Defies 'Valuation' (Technical Analysis)
Jun 10Crispr Therapeutics' Strategic Moves Amidst Gene Therapy Challenges (Rating Upgrade)
Jun 03Shareholders Will Probably Hold Off On Increasing CRISPR Therapeutics AG's (NASDAQ:CRSP) CEO Compensation For The Time Being
May 23Newsflash: CRISPR Therapeutics AG (NASDAQ:CRSP) Analysts Have Been Trimming Their Revenue Forecasts
May 13We're Not Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn
May 10Crispr Therapeutics Q1 Earnings: Casgevy Launch Tip Of Gene Editing Iceberg
May 09Crispr Therapeutics: Market Misunderstanding Is Your Buying Opportunity (Upgrade)
May 03Crispr Therapeutics: Now Is The Time To Buy
Apr 24Calculating The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Apr 16Crispr Therapeutics: CASGEVY Commercial Launch Is Taking Shape
Mar 26There's Reason For Concern Over CRISPR Therapeutics AG's (NASDAQ:CRSP) Massive 26% Price Jump
Feb 22Crispr Therapeutics: Cautiously Optimistic
Feb 22Crispr Therapeutics: Investors Bet Against Casgevy Uptake
Feb 01Crispr Therapeutics: Commercial Validation Is The Next Step
Jan 18Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry
Jan 11CRISPR Therapeutics AG's (NASDAQ:CRSP) Popularity With Investors Is Under Threat From Overpricing
Dec 25CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans
Nov 02A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Oct 05CRISPR Therapeutics AG's (NASDAQ:CRSP) Business Is Yet to Catch Up With Its Share Price
Sep 14We're Not Very Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Rate
Jul 24Calculating The Fair Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Jun 28CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans
Apr 02CRISPR Therapeutics AG's (NASDAQ:CRSP) Intrinsic Value Is Potentially 34% Above Its Share Price
Mar 06Companies Like CRISPR Therapeutics (NASDAQ:CRSP) Are In A Position To Invest In Growth
Dec 08CRISPR CAR T cell therapy for skin/blood cancer gets FDA regenerative medicine tag
Sep 28Crispr: Elucidating And Forecasting Key Developments
Sep 21Opbrengsten en kosten
Hoe CRISPR Therapeutics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Sep 24 | 203 | -240 | 71 | 0 |
30 Jun 24 | 202 | -266 | 72 | 0 |
31 Mar 24 | 272 | -217 | 72 | 0 |
31 Dec 23 | 371 | -154 | 76 | 0 |
30 Sep 23 | 170 | -354 | 81 | 0 |
30 Jun 23 | 170 | -416 | 90 | 0 |
31 Mar 23 | 100 | -524 | 97 | 0 |
31 Dec 22 | 1 | -650 | 102 | 0 |
30 Sep 22 | 14 | -681 | 105 | 0 |
30 Jun 22 | 15 | -633 | 102 | 0 |
31 Mar 22 | 915 | 312 | 103 | 0 |
31 Dec 21 | 915 | 378 | 100 | 0 |
30 Sep 21 | 902 | 412 | 102 | 0 |
30 Jun 21 | 902 | 447 | 100 | 0 |
31 Mar 21 | 1 | -392 | 93 | 0 |
31 Dec 20 | 1 | -349 | 86 | 0 |
30 Sep 20 | 77 | -211 | 80 | 0 |
30 Jun 20 | 289 | 20 | 74 | 0 |
31 Mar 20 | 289 | 46 | 68 | 0 |
31 Dec 19 | 290 | 67 | 63 | 0 |
30 Sep 19 | 213 | -11 | 63 | 0 |
30 Jun 19 | 1 | -200 | 57 | 0 |
31 Mar 19 | 2 | -185 | 54 | 0 |
31 Dec 18 | 3 | -165 | 48 | 0 |
30 Sep 18 | 35 | -117 | 43 | 0 |
30 Jun 18 | 37 | -91 | 41 | 0 |
31 Mar 18 | 40 | -75 | 36 | 0 |
31 Dec 17 | 41 | -68 | 36 | 0 |
30 Sep 17 | 11 | -51 | 35 | 0 |
30 Jun 17 | 10 | -41 | 31 | 0 |
31 Mar 17 | 7 | -36 | 32 | 0 |
31 Dec 16 | 5 | -23 | 31 | 0 |
30 Sep 16 | 3 | -53 | 25 | 0 |
30 Jun 16 | 2 | -44 | 24 | 0 |
31 Mar 16 | 1 | -31 | 17 | 0 |
31 Dec 15 | 0 | -26 | 13 | 0 |
Kwaliteitswinsten: CRSP is momenteel verliesgevend.
Groeiende winstmarge: CRSP is momenteel verliesgevend.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: CRSP is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 27% per jaar.
Versnelling van de groei: Het is niet mogelijk om de winstgroei van CRSP over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.
Winst versus industrie: CRSP is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( 16.6% ).
Rendement op eigen vermogen
Hoge ROE: CRSP heeft een negatief Return on Equity ( -12.35% ), omdat het momenteel verliesgevend is.